In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Specialty LP

Division of Mylan NV
www.mylanspecialty.com

Latest From Mylan Specialty LP

US FDA's New Paragraph IV Data Further Illustrates Generic Competition Problems

Data on the number of ANDAs submitted with valid paragraph IV certifications shows some products with strong generic interest and others with almost none.

Generic Drugs Legal Issues

Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth

The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.

Combination Products Market Intelligence

Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement

Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.

Reimbursement Compliance

Mylan’s EpiPen Recall: Another Hit On The Auto-Injector

What began as an overseas recall of one lot made by a Pfizer subsidiary is expanding, threatening to besmirch Mylan’s once golden supply-chain quality record. The recall follows pricing controversy around the EpiPen product got the CEO hauled before Congress.

Safety Combination Products
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Dey Pharma LP
  • Dey Laboratories
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • Roger Graham, Pres.
  • Contact Info
  • Mylan Specialty LP
    Phone: (908) 542-1999
    110 Allen Rd., 4th Fl.
    Basking Ridge, NJ 07920
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register